Stryker’s cyber-driven selloff may offer investors a rare discount on a best-in-class medtech compounder powered by robotics, recurring implants, aging demographics, and hospital ecosystem lock-in.
Overview
Stryker is a global medtech leader with strong positions in Orthopaedics, MedSurg, Neurotechnology, and Spine. Fiscal 2025 sales rose 11.2% to $25.1 billion, supported by procedure growth, Mako robotics, recurring implants and consumables, and acquisitions such as Inari Medical. The U.S. remains its largest market, while aging demographics create long-term demand for joint replacement, stroke care, and surgical automation. A major 2026 cyber incident disrupted operations, but underlying procedure demand and platform loyalty appear resilient.